Final follow-up results suggest Opdivo and Yervoy could be close to a cure for some people with advanced melanoma, shifting how doctors administer follow-up care.

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

Roche has now beat Merck and Bristol Myers to market with its under-the-skin immunotherapy. Elsewhere, Sanofi bought into radiopharmaceuticals and Mene Pangalos joined Biogen's board.

During an investor presentation Thursday, executives admitted to being overly optimistic their vaccine could wrest significant market share away from GSK's and Pfizer's products this year.

Avalere Health is proud to announce the appointment of Corrina Safeio as its new President, Global Marketing and EVP, ...

ONTOFORCE, a leader in semantic technology for life sciences, announces the launch of DISQOVER 7, the most advanced version ...

The offerings by Bicara, Zenas and MBX give a glimpse into what industry insiders describe as a backlog of mature startups waiting for the right opportunity to test public markets.

The funding, from AMR Action Fund and others, will help U.K.-based F2G complete late testing of a treatment that the FDA rejected one year ago.

Vironexis, a biotech spun out of research at Nationwide Children’s Hospital, claims it will be the first company to start a study testing a cancer drug delivered via the adeno-associated viruses ...

As part of a broad restructuring, the company revealed plans to reduce research spending by 20% over the next few years and ax five programs in early development. It won’t cut jobs, however, a ...

The Biosecure Act, which limits contracts with WuXi AppTec, WuXi Biologics and three other companies, still needs Senate support to advance.

Study results provide much-anticipated details to Summit’s claim earlier this year that its drug “decisively beat” Merck’s dominant immunotherapy.